Antibody Engineering & Therapeutics Europe

Join us for The Antibody Society’s 2nd annual Antibody Engineering & Therapeutics Europe meeting, where you will connect with industry and academic scientists and executives from Europe and around the world focused on antibody and protein therapeutic discovery and development.
Keynote speakers Jane Osbourn, Ph.D., (Vice President R&D and Site Leader of Medimmune) will discuss antibody therapeutic developments, pipeline and progress at Medimmune and Hans Clevers, M.D., Ph.D., (Group Leader, Hubrecht Institute for Developmental Biology and Stem Cell Research and Professor of Molecular Genetics, University Medical Center Utrecht and Utrecht University) will discuss Lgr5 stem cell-based organoids and their applications in cancer research. In addition, the meeting features sessions on Turning Antibody Leads into Drugs, Recent Advances in Immuno-Oncology Approaches, Bioinformatics and Repertoires in Antibody Discovery and Development, Antibody Therapeutics for Autoimmune and Neurodegenerative Diseases, Clinical Developments in Antibody Therapeutics, and New Antibody Formats and Effector Functions.

Society members save 15% on the registration fee when using the code Antibody15!

2018

The Society’s inaugural Antibody Engineering & Therapeutics Europe meeting was held June 5-7, 2018, in Amsterdam. Members of the Society served as the Scientific Advisors and session Chairs. The meeting featured:

CAR-T & anti-CD3-based Bispecifics, moderated by Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London and President of The Antibody Society, United Kingdom and David Gilham, Ph.D., Vice President of Research and Development, Celyad S.A., Belgium.